AI Advances Drug Discovery with $1.5 Billion AstraZeneca-Insitro Partnership

Recent news in biopharma AI includes a significant $1.5 billion partnership between AstraZeneca and insitro, leveraging insitro's AI platform for cardiometabolic disease research. This collaboration aims to identify new drug targets and accelerate the discovery of novel medicines by applying machine learning and human genetics.